2016-2020 Strategy: Progress Challenges and Risks

BOARD MEETING
Anuradha Gupta
28-29 November 2018, Geneva, Switzerland
Alliance on track to achieve its 2020 mission indicators

- **Under-5 Mortality**: 62 per 1,000 (2015 Baseline) → 57 per 1,000 (2020 Target) → 56 per 1,000 (2020 Target)
- **Children Immunised (with Gavi Support)**: 0 (2015 Baseline) → 127 million (2020 Target) → 300 million (2020 Target)
- **Future Deaths Averted**: 0 (2015 Baseline) → 2.5 million (2020 Target) → 5-6 million (2020 Target)
- **Future DALYS Averted**: 0 (2015 Baseline) → 105 million (2020 Target) → 250 million (2020 Target)
- **Vaccines Sustained (after Gavi support ends)**: N/A (2015 Baseline) → 100% (2020 Target)
SG1: Accelerate vaccines
Mixed performance: challenges and risks remain

**Coverage**
- DTP3:
  - 2015: 79%
  - 2016: 80%
  - 2017: 80%
  - 2020: 84%
- MCV1:
  - 2015: 78%
  - 2016: 78%
  - 2017: 78%
  - 2020: 83%

**Breadth of Protection**
- Increasing:
  - 2015: 31%
  - 2016: 37%
  - 2017: 41%
  - 2020: 62%

**Geographic Equity**
- Initial improvement:
  - 2015: 79%
  - 2016: 80%
  - 2017: 84%
  - 2020: 89%

**Maternal & Wealth Equity**
- No change:
  - Wealth:
    - 2015: 19%
    - 2016: 19%
    - 2017: 19%
    - 2020: 16%
  - Maternal education:
    - 2015: 19%
    - 2016: 19%
    - 2017: 19%
    - 2020: 15%
Diphtheria outbreaks: reminder of gaps in routine immunisation

Haiti

- 601 cases
- DTP3 Coverage 2017: 60, 58, 60

Yemen

- 2,081 cases
- Diphtheria-associated deaths (WHO, 15/08/17 - 10/02/18): 69, 71, 68

Bangladesh

- Cox’s Bazar district
- 7,062 cases
- Diphtheria-associated deaths (WHO, 15/08/17 - 10/02/18): 97, 97, 97

SG1: Accelerate vaccines
SG2: Strengthen systems
Strengthening routine immunisation delivery: Strategic shifts but more work to be done

Key levers

- Health System Strengthening (HSS)
- Partners’ Engagement Framework (PEF)
- Innovation & private sector partnerships
- Collaboration with other financing institutions
- Advocacy for political will
DRC: Using all Gavi levers to improve coverage and equity

Subnational focus in 9 provinces

**Political will**
Sustained Alliance engagement

**LMC**
“Mashako plan” in 9 provinces

**Supply Chain**
Cold chain equipment to expand from 16% to 80% health facilities

**Innovations**
Exploration of vaccine delivery by drones

**CSOs**
Social mobilization in 20,000 villages

**Data**
DHIS2 rollout and HMIS strengthening

**Collaboration with Global Fund, WB and GFF**
on performance based financing
Emerging risks in high coverage countries

Recent drop in coverage in Kyrgyzstan (Penta3)

Subnational level coverage Penta3

SG2: Strengthen systems

Surviving infants

Coverage (%)

Denser / Urban areas

Bishkek City
Osh
Chu
Djalal-Abad
Batken
Issyk-Kul
Naryn
SG3: Improve sustainability
Gavi leading the way on sustainability

### CO-FINANCING & SELF-FINANCING

<table>
<thead>
<tr>
<th>Year</th>
<th>Co-financing</th>
<th>Self Financing (incl. India)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>$125m</td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td>$103m</td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td>$136m</td>
<td>$162m</td>
</tr>
</tbody>
</table>

- Self-financing of countries that transitioned out:
  - 2015: $125m
  - 2016: $135m
  - 2017: $136m

### COUNTRIES INVESTMENT IN VACCINES

- Increasing:
  - 2015: 49%
  - 2016: 54%
  - 2017: 100%
  - 2020: 100%

- (% of countries increasing domestic expenditure on RI)

### COUNTRIES ON TRACK TO TRANSITION

- Challenges:
  - 2015: 63%
  - 2016: 79%
  - 2017: 53%
  - 2020: 75%

- (% of countries "on track" for successful transition)

### CO-FINANCING COMMITMENTS

- Continued performance:
  - 2015: 85%
  - 2016: 100%
  - 2017: 100%
  - 2020: 100%

- (% of countries meeting their co-financing commitments excluding waivers)
Successful market shaping for vaccines; new risks are emerging

**Vaccine Price Reduction**
- 2015: $20
- 2016: $19
- 2017: $17
- 2020: N/A

(Cost of full course of Penta, PCV and Rota vaccines)

**Supply Security**
- 2015: 7/11
- 2016: 9/11
- 2017: 8/11
- 2020: 11/11

(Vaccine markets where supply meets demand)

**Healthy Market Dynamics**
- 2015: 1
- 2016: 2
- 2017: 3
- 2020: 6/11

(Vaccine markets classified with moderate or high healthy dynamics)

**Vaccine Innovation**
- 2015: 0
- 2016: 3
- 2017: 5
- 2020: 10

(No. vaccines & immunisation products with improved characteristics)
Key risks are evolving and being monitored

Potential impact on the ability of the Alliance to achieve the Gavi mission, given reactive mitigation in place to address the potential consequences once the risk materialises

Programmatic risk
Corporate risk
Recent evolution

Very high risks
a) Country management capacity
b) Data quality ▼
c) Ability to reach the under-immunised ▼
d) Sustainable transition

High risks
e) Insufficient demand
f) Outbreaks disrupt immunisation
g) Misuse by countries
h) Donor support
i) Polio transition NEW
j) IT disruption NEW
k) Strategic relevance
l) Frequent or unplanned campaigns △
m) Partner capacity▼
n) Global supply shortages
o) HSIS value for money
p) Forecasting variability
q) Secretariat disruption ▼

Likelihood of occurrence, given preventive mitigation in place to address the potential causes

Highly likely
Highly unlikely
Low impact
High impact